Cutaneous apocrine adenocarcinoma: Defining epidemiology, outcomes, and optimal therapy for a rare neoplasm
Article first published online: 12 SEP 2011
Copyright © 2011 Wiley Periodicals, Inc.
Journal of Surgical Oncology
Volume 105, Issue 4, pages 415–419, 15 March 2012
How to Cite
Hollowell, K. L., Agle, S. C., Zervos, E. E. and Fitzgerald, T. L. (2012), Cutaneous apocrine adenocarcinoma: Defining epidemiology, outcomes, and optimal therapy for a rare neoplasm. J. Surg. Oncol., 105: 415–419. doi: 10.1002/jso.22023
- Issue published online: 6 FEB 2012
- Article first published online: 12 SEP 2011
- Manuscript Accepted: 16 JUN 2011
- Manuscript Received: 4 NOV 2010
- cutaneous neoplasm;
- seer registry;
- sentinel lymph node
Background and Objectives
Apocrine adenocarcinoma is a rare neoplasm. There is a paucity of data on demographics and survival with no clear consensus on management of at risk lymph nodes, therefore, we analyzed a large cohort of patients identified via a national tumor registry.
Patients ages 17–91 from 1973 to 2006 were identified in the SEER registry and excluded breast and non-cutaneous neoplasms. Data analyzed included basic demographics, survival, surgical therapy, and stage.
A total of 186 patients with apocrine adenocarcinoma were identified. The median age was 67 years, 76% were white and there was an equal distribution of males and females. The most common site was trunk (53%) followed by head and neck (35%). Surgery was performed on most patients (96%), either excision (50%) or wide excision (30%). Lymph node metastases were present in 69% patients undergoing node surgery. Median overall survival was 51.5 months. Positive lymph node status (P = 0.006) and metastatic disease (P < 0.001) were associated with diminished overall survival.
Cutaneous apocrine adenocarcinoma is a rare neoplasm. Excision is standard treatment. The most important predictor of survival in localized disease is lymph node status; therefore, sentinel lymph node biopsy could be considered in management of this disease. J. Surg. Oncol. 2012;105:415–419. © 2011 Wiley Periodicals, Inc.